Where this myeloma information comes from
On this page are the major sources of information that we use to put together this section of CancerHelp UK.
All our information is checked by cancer specialists and surgeons who specialise in treating cancer. The names of our specialist reviewers are at the end of this list. We also try to find patients to review all our sections. If you have had multiple myeloma, live in the UK and would like to become a patient reviewer, you can write to us by clicking on contact us.
Cancer Research UK
CancerStats Series
US National Cancer Institute
Information on the treatment of multiple myeloma
www.cancer.gov/cancerinfo/types/myeloma/
Principles and practice of oncology (8th edition)
De Vita, V.T., Hellman, S. and Rosenberg S.A.
Lippincott, Williams and Wilkins, 2008
Cancer and its management (6th edition)
Tobias J and Hochhauser D
Blackwell Publishing Ltd, 2010
Guidance on Cancer Services - improving outcomes in haematological cancers - the manual
The National Institute for Health and Clinical Excellence (NICE), 2003
Link to the haematological guidelines on the NICE website
Referral guidelines for suspected cancers
The National Institute for Health and Clinical Excellence (NICE), June 2005
Link to the referral guidelines on the NICE website
Guidelines on the Diagnosis and Management of Multiple Myeloma
British Committee for Standards in Haematology (BCSH) in conjunction with the UK Myeloma Forum (UKMF), September 2010
Guidelines for Supportive Care in Myeloma
British Committee for Standards in Haematology (BCSH) in conjunction with the UK Myeloma Forum (UKMF), September 2010
The National Institute for Health and Clinical Excellence (NICE) Technology Appraisals
- Percutaneous vertebroplasty, September 2003
- Balloon kyphoplasty for vertebral compression fractures, April 2006
- Bortezomib monotherapy for relapsed multiple myeloma, October 2007
- Multiple Myeloma - lenalidomide, June 2009
- Multiple Myeloma (first line) - bortezomib and thalidomide (Final Appraisal Determination), August 2010
The Scottish Medicines Consortium (SMC) guidance
- Thalidomide, January 2009
- Pegylated liposomal doxorubicin in combination with bortezomib (Caelyx plus Velcade), July 2009
- Bortezomib (Velcade), November 2009
- Lenalidomide (Revlimid), May 2010
The All Wales Medicines Strategy Group (AWMSG) guidance
- Bortezomib (Velcade), April 2010
- Thalidomide in combination with melphalan and prednisone as first line treatment, February 2009
Clinical course of patients with relapsed myeloma. Kumar SK et al. Mayo Clinic Proceedings (2004), 79, (7), 867-74.
Bisphosphonates in multiple myeloma. Cochrane Review. Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Cochrane Database of Systematic Reviews. 2010. Issue 3, DOI: 10.1002/14651858.CD003188.pub2.
Early versus deferred treatment for early stage multiple myeloma. Cochrane Review. He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B. Cochrane Database of Systematic Reviews, issue 1, 2003. DOI: 10.1002/14651858.CD004023
Multiple myeloma seminar. Sirohi, B. and Powles, R. The Lancet (2004) 363, (9412), 875-887.
Guidelines on the diagnosis and management of multiple myeloma. Smith, A., Wisloff, F. and Samson, D. 2005. British Journal of Haematology, (2005), 132, 410-451.
New drugs for the treatment of multiple myeloma. Bruno, B., Rotta, M., Giaccone, L., Massaia, M., Bertola, A., Palumbo, A. and Boccadoro, M. The Lancet Oncology, (2004), 5, (7), 430 - 442.
Guidelines for the use of imaging in the management of myeloma. D'Sa S et al, British Journal of Haematology, (2007) 137(1):49-63
First line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Morgan G, Davies F and Gregory W et al. The Lancet (2010) 376: 1989-1999. DOI: 10.1016/S0140-6736(10)62051-X
Multiple myeloma - current issues and controversies. Kumar S. Cancer Treatment Reviews (2010) 36S2: S3-S11:
Dee McLean - McDee Art, Medical Illustration






